In vivo, WNT inhibition in a p185<sup>BCR-ABL</sup>Arf<sup>-/-</sup> B-ALL mouse model sensitised leukaemia cells to chemotherapy, delaying relapse and extending survival. Here, CDKN2A is linked to leukemia.